{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:13:07Z","timestamp":1788480787143,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C1094854"],"award-info":[{"award-number":["NRF-2021R1A2C1094854"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020M3A9G3080281"],"award-info":[{"award-number":["NRF-2020M3A9G3080281"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-19252970"],"award-info":[{"award-number":["RS-2025-19252970"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sepsis is a life-threatening syndrome characterized by a dysregulated host response to infection, leading to multiorgan dysfunction. Inflammasome activation and pyroptosis are key mechanisms driving sepsis-associated organ dysfunction. However, it remains unclear whether circulating biomarkers actively contribute to disease progression. Although galectin-3-binding protein (LGALS3BP) has been proposed as a diagnostic and prognostic marker of sepsis, its functional role in sepsis-associated organ dysfunction remains undefined. In this study, the dynamics and function of LGALS3BP in sepsis were investigated using cecal ligation and puncture (CLP) and lipopolysaccharide (LPS)-induced mouse models. Plasma LGALS3BP levels were markedly elevated during sepsis and were accompanied by increased LGALS3BP expression in multiple organs, particularly in the liver. Hepatocyte-specific LGALS3BP overexpression exacerbated sepsis-associated liver injury, as evidenced by elevated serum alanine aminotransferase and aspartate aminotransferase levels, increased hepatocyte death, and reduced survival. Transcriptomic profiling of septic livers revealed that LGALS3BP overexpression markedly enriched cytokine signaling, inflammatory response gene sets, and the pyroptosis pathway, indicating dysregulated immune responses and an injury-driven transcriptional program during sepsis. RNA sequencing and in vitro experiments using primary hepatocytes treated with recombinant LGALS3BP, which mimics secreted LGALS3BP, demonstrated that recombinant LGALS3BP increased pyroptosis-associated gene signatures but was not sufficient to induce pyroptotic cell death. Instead, recombinant LGALS3BP promoted pyroptotic cell death only in the presence of septic stimuli. Mechanistically, under septic conditions, secretory LGALS3BP activated the TLR2\u2013IRF3\u2013NF-\u03baB signaling axis, leading to NLRP3 inflammasome activation, cleavage of caspase-1 and gasdermin D, and increased IL-1\u03b2 and IL-18 release, thereby promoting pyroptotic cell death. Importantly, antibody-mediated neutralization of secretory LGALS3BP suppressed TLR2\u2013IRF3\u2013NF-\u03baB signaling and concomitantly attenuated inflammasome activation and pyroptosis in hepatocytes. Collectively, these findings identify LGALS3BP as a key pathogenic driver of sepsis-associated liver dysfunction through pyroptosis-mediated hepatocyte injury. Therapeutic targeting of LGALS3BP may therefore represent a promising strategy to mitigate sepsis-related liver failure beyond its proposed role as a circulating biomarker.<\/jats:p>","DOI":"10.1038\/s41420-026-03198-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:27:02Z","timestamp":1782192422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secretory LGALS3BP exacerbates sepsis-associated liver dysfunction by activating inflammasome-mediated pyroptosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Jun-Eul","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jeong","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Ra","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Kook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Kyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-7862","authenticated-orcid":false,"given":"Sang-Hee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik-Joo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-6966","authenticated-orcid":false,"given":"Eun-Gene","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3198_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"3198_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41392-021-00816-9","volume":"6","author":"YY Zhang","year":"2021","unstructured":"Zhang YY, Ning BT. Signaling pathways and intervention therapies in sepsis. Signal Transd Target Ther. 2021;6:407.","journal-title":"Signal Transd Target Ther"},{"key":"3198_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200\u201311.","journal-title":"Lancet"},{"key":"3198_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jama.2016.20328","volume":"317","author":"EP Raith","year":"2017","unstructured":"Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017;317:290\u2013300.","journal-title":"JAMA"},{"key":"3198_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/CCM.0B013E318165BABB","volume":"36","author":"KL Becker","year":"2008","unstructured":"Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941\u201352.","journal-title":"Crit Care Med"},{"key":"3198_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4618-7","volume":"19","author":"J Song","year":"2019","unstructured":"Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value of interleukin-6, PENTRAXIN 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019;19:968.","journal-title":"BMC Infect Dis"},{"key":"3198_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/cc8872","volume":"14","author":"C Pierrakos","year":"2010","unstructured":"Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.","journal-title":"Crit Care"},{"key":"3198_CR8","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.","journal-title":"Nat Rev Dis Primers"},{"key":"3198_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-016-0544-7","volume":"18","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Rubenfeld GD. Understanding long-term outcomes following sepsis: implications and challenges. Curr Infect Dis Rep. 2016;18:37.","journal-title":"Curr Infect Dis Rep"},{"key":"3198_CR10","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1016\/j.immuni.2021.10.012","volume":"54","author":"T van der Poll","year":"2021","unstructured":"van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021;54:2450\u201364.","journal-title":"Immunity"},{"key":"3198_CR11","doi-asserted-by":"publisher","first-page":"14245","DOI":"10.1016\/S0021-9258(19)85233-X","volume":"268","author":"K Koths","year":"1993","unstructured":"Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 1993;268:14245\u201349.","journal-title":"J Biol Chem"},{"key":"3198_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1023\/B:GLYC.0000014085.00706.d4","volume":"19","author":"A Grassadonia","year":"2002","unstructured":"Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J. 2002;19:551\u201356.","journal-title":"Glycoconj J"},{"key":"3198_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41577-022-00829-7","volume":"23","author":"FT Liu","year":"2023","unstructured":"Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23:479\u201394.","journal-title":"Nat Rev Immunol"},{"key":"3198_CR14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3389\/fimmu.2019.01760","volume":"10","author":"CS Hong","year":"2019","unstructured":"Hong CS, Park MR, Sun EG, Choi W, Hwang JE, Bae WK, et al. Gal-3BP negatively regulates NF-\u03baB signaling by inhibiting the activation of TAK1. Front Immunol. 2019;10:1760.","journal-title":"Front Immunol"},{"key":"3198_CR15","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3390\/ijms24043955","volume":"24","author":"PL Pesole","year":"2023","unstructured":"Pesole PL, Liso M, Donghia R, Guerra V, Lippolis A, Mastronardi M, et al. 90K\/Mac-2 BP is a new predictive biomarker of response to infliximab therapy in IBD patients. Int J Mol Sci. 2023;24:3955.","journal-title":"Int J Mol Sci"},{"key":"3198_CR16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.55563\/clinexprheumatol\/ol0vqj","volume":"39","author":"ASR Peretz","year":"2021","unstructured":"Peretz ASR, Rasmussen NS, Jacobsen S, Sj\u00f6wall C, Nielsen CT. Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39:1360\u201368.","journal-title":"Clin Exp Rheumatol"},{"key":"3198_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/tmj.tmj_23_18","volume":"46","author":"S Abo-Elyazeed","year":"2018","unstructured":"Abo-Elyazeed S, Gheida S, Soliman G, Gamea M. Plasma galectin-3-binding protein level in patients with systemic lupus erythematosus. Tanta Med J. 2018;46:249.","journal-title":"Tanta Med J"},{"key":"3198_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.42382","volume":"75","author":"H El Bannoudi","year":"2023","unstructured":"El Bannoudi H, Cornwell M, Luttrell-Williams E, Engel A, Rolling C, Barrett TJ, et al. Platelet LGALS3BP as a mediator of myeloid inflammation in systemic lupus erythematosus. Arthritis Rheumatol. 2023;75:711\u201322.","journal-title":"Arthritis Rheumatol"},{"key":"3198_CR19","doi-asserted-by":"publisher","first-page":"101491","DOI":"10.1016\/j.jhepr.2025.101491","volume":"7","author":"PC Lee","year":"2025","unstructured":"Lee PC, Wu CJ, Lee IC, Lee CJ, Hou MC, Huang YH. Serum fibrosis marker M2BPGi-based novel score predicts survival of unresectable HCC undergoing immunotherapy. JHEP Rep. 2025;7:101491.","journal-title":"JHEP Rep"},{"key":"3198_CR20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/cac2.12600","volume":"44","author":"DH Kim","year":"2024","unstructured":"Kim DH, Sung M, Park MS, Sun EG, Yoon S, Yoo KH, et al. Galectin 3-binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor-\u03b21 (TGF-\u03b21) availability and inhibits hepatocarcinogenesis. Cancer Commun. 2024;44:1106\u201329.","journal-title":"Cancer Commun"},{"key":"3198_CR21","doi-asserted-by":"publisher","first-page":"102471","DOI":"10.1016\/j.tice.2024.102471","volume":"89","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liang L, Li J, Pang T, Zhang SH, Xia ZY. Aberrant expression of LGALS3BP drives an unfavorable prognosis and more aggressive in HCC via regulating PI3K\/AKT signaling. Tissue Cell. 2024;89:102471.","journal-title":"Tissue Cell"},{"key":"3198_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01958-8","volume":"27","author":"SS Kim","year":"2025","unstructured":"Kim SS, Park I, Kim J, Ka NL, Lim GY, Park MY, et al. Secreted LGALS3BP facilitates distant metastasis of breast cancer. Breast Cancer Res. 2025;27:4.","journal-title":"Breast Cancer Res"},{"key":"3198_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-021-00447-7","volume":"7","author":"SH Cho","year":"2021","unstructured":"Cho SH, Shim HJ, Park MR, Choi JN, Akanda MR, Hwang JE, et al. Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-\u03baB signaling. Cell Death Discov. 2021;7:65.","journal-title":"Cell Death Discov"},{"key":"3198_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3803\/EnM.2025.2448","volume":"41","author":"M Sung","year":"2025","unstructured":"Sung M, Kim DH, Sun EG, Hwang JE, Cho SH, Chung IJ. et al. LGALS3BP induces insulin resistance via TLR2-IKK\u03b1\/\u03b2 pathway-mediated IRS1 serine phosphorylation. Endocrinol Metab. 2025;41:121\u2013137.","journal-title":"Endocrinol Metab"},{"key":"3198_CR25","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.2147\/IDR.S468298","volume":"17","author":"D Ji","year":"2024","unstructured":"Ji D, Li J, Liu A, Ye R, Zhang S, Gao L, et al. Predictive value of combined detection of serum LGALS3BP and GDF-15 for the prognosis of ICU sepsis patients. Infect Drug Resist. 2024;17:4417\u201326.","journal-title":"Infect Drug Resist"},{"key":"3198_CR26","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.2147\/IDR.S316402","volume":"14","author":"M Luo","year":"2021","unstructured":"Luo M, Zhang Q, Hu Y, Sun C, Sheng Y, Deng C. LGALS3BP: a potential plasma biomarker associated with diagnosis and prognosis in patients with sepsis. Infect Drug Resist. 2021;14:2863\u201371.","journal-title":"Infect Drug Resist"},{"key":"3198_CR27","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1007\/s10238-023-01077-2","volume":"23","author":"L Bosquillon de Jarcy","year":"2023","unstructured":"Bosquillon de Jarcy L, Akbil B, Mhlekude B, Leyens J, Postmus D, Harnisch G, et al. 90K\/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection. Clin Exp Med. 2023;23:3689\u20133700.","journal-title":"Clin Exp Med"},{"key":"3198_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23494-1","volume":"12","author":"C Gutmann","year":"2021","unstructured":"Gutmann C, Takov K, Burnap SA, Singh B, Ali H, Theofilatos K, et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat Commun. 2021;12:3406.","journal-title":"Nat Commun"},{"key":"3198_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/diagnostics15070937","volume":"15","author":"M Park","year":"2025","unstructured":"Park M, Hur M, Kim H, Lee CH, Lee JH, Kim HW, et al. Novel usefulness of M2BPGi for predicting severity and clinical outcomes in hospitalized COVID-19 patients. Diagnostics. 2025;15:937.","journal-title":"Diagnostics"},{"key":"3198_CR30","doi-asserted-by":"publisher","first-page":"962139","DOI":"10.3389\/fcimb.2022.962139","volume":"12","author":"R Wen","year":"2022","unstructured":"Wen R, Liu YP, Tong XX, Zhang TN, Yang N. Molecular mechanisms and functions of pyroptosis in sepsis and sepsis-associated organ dysfunction. Front Cell Infect Microbiol. 2022;12:962139.","journal-title":"Front Cell Infect Microbiol"},{"key":"3198_CR31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cells14120930","volume":"14","author":"Saavedra-Torres","year":"2025","unstructured":"Saavedra-Torres, Pinz\u00f3n-Fern\u00e1ndez JS, Ocampo-Posada MV, Nati-Castillo M, Jim\u00e9nez Hincapie LA HA, Cadrazo-Gil EJ, et al. Inflammasomes and signaling pathways: key mechanisms in the pathophysiology of sepsis. Cells. 2025;14:930.","journal-title":"Cells"},{"key":"3198_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660\u201365.","journal-title":"Nature"},{"key":"3198_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02985-x","volume":"11","author":"B Bai","year":"2020","unstructured":"Bai B, Yang Y, Wang Q, Li M, Tian C, Liu Y, et al. NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis. 2020;11:776.","journal-title":"Cell Death Dis"},{"key":"3198_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2025.09.006","volume":"86","author":"Y Ma","year":"2025","unstructured":"Ma Y, Meng J, Sun F, Lei M. Targeting the NLRP3 inflammasome in sepsis: molecular mechanisms and therapeutic strategies. Cytokine Growth Factor Rev. 2025;86:57\u201370.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3198_CR35","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.26592","volume":"59","author":"A Wree","year":"2014","unstructured":"Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898\u2013910.","journal-title":"Hepatology"},{"key":"3198_CR36","doi-asserted-by":"publisher","first-page":"104345","DOI":"10.1016\/j.ebiom.2022.104363","volume":"86","author":"WJ Wiersinga","year":"2022","unstructured":"Wiersinga WJ, van der Poll T. Immunopathophysiology of human sepsis. EBiomedicine. 2022;86:104345.","journal-title":"EBiomedicine"},{"key":"3198_CR37","first-page":"246","volume":"23","author":"J Ren","year":"2022","unstructured":"Ren J, Ren J, Pan Y. The expression of serum LGALS3BP, FGF-21, Trx-1 and their relationship with prognosis in patients with sepsis. J Clin Emerg. 2022;23:246\u201350.","journal-title":"J Clin Emerg"},{"key":"3198_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-024-00679-z","volume":"26","author":"SI Lee","year":"2025","unstructured":"Lee SI, Kim NY, Chung C, Park D, Kang DH, Kim DK, et al. IL-6 and PD-1 antibody blockade combination therapy regulate inflammation and T lymphocyte apoptosis in murine model of sepsis. BMC Immunol. 2025;26:3.","journal-title":"BMC Immunol"},{"key":"3198_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00603-z","volume":"18","author":"S Xu","year":"2020","unstructured":"Xu S, Pan X, Mao L, Pan H, Xu W, Hu Y, et al. Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation. Cell Commun Signal. 2020;18:104.","journal-title":"Cell Commun Signal"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03198-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03198-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:28:18Z","timestamp":1788478098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03198-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3198"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03198-5","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All mice were maintained in a specific pathogen-free facility with free access to food and water. All animal experiments were performed in accordance with institutional and national guidelines for the care and use of laboratory animals. The experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Chonnam National University Medical School (Approval No. CNU IACUC-H-2023-5).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"355"}}